ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, single-centre, non-randomised study to evaluate the
absorption, distribution, metabolism, and excretion (ADME) of an oral solution of
[14C]-ibrexafungerp following administration in healthy male subjects.
Each subject will receive a single dose of [14C]-ibrexafungerp and will be followed for up to
20 days. During this period total radioactivity will be measured in blood, urine and faeces.